Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sonia Rozette"'
Autor:
Anne-Sophie Hamy, Lauren Darrigues, Enora Laas, Diane De Croze, Lucian Topciu, Giang-Thanh Lam, Clemence Evrevin, Sonia Rozette, Lucie Laot, Florence Lerebours, Jean-Yves Pierga, Marie Osdoit, Matthieu Faron, Jean-Guillaume Feron, Marick Laé, Fabien Reyal
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234191 (2020)
IntroductionThe Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. The objective of this work is to independently evalu
Externí odkaz:
https://doaj.org/article/00a331b30e81432888d7d03ba4451387
Autor:
Jean-Yves Pierga, Marick Laé, Lucie Laot, Sonia Rozette, Fabien Reyal, Florence Coussy, Audrey Bellesoeur, Thomas Gaillard, Anne-Sophie Hamy, Beatriz Grandal, Eléonore De Guillebon, Clemence Evrevin, Jean Guillaume Feron, Enora Laas
Publikováno v:
Cancer Research. 80:P2-16
BACKGROUND: Although no survival benefit has been demonstrated by treating early breast cancer (BC) with neoadjuvant chemotherapy (NAC), it is now widely accepted as first intention strategy in triple negative and HER2-positive BC. However, the benef
Autor:
Jean Guillaume Feron, Audrey Bellesoeur, Beatriz Grandal, Arnaud Bresset, Clemence Evrevin, Fabien Reyal, Sonia Rozette, Eléonore De Guillebon, Anne-Sophie Hamy, Enora Laas, Florence Coussy, Marick Laé, Thomas Gaillard, Jean-Yves Pierga
Publikováno v:
Cancer Research. 80:P2-16
INTRODUCTION: Neoadjuvant chemotherapy (NAC) is increasingly being used for locally advanced breast cancers (BCs) or aggressive BC tumors. However, no survival benefit of the neoadjuvant approach over receiving chemotherapy in the adjuvant setting ha
Autor:
Dominique Stoppa-Lyonnet, Fabien Reyal, Claire Saule, Clemence Evrevin, Sonia Rozette, Beatriz Grandal, Marick Laé, Jean-Yves Pierga, Etienne Brain, Anne-Sophie Hamy, Elise Dumas, Enora Laas, Lucie Laot, Isabelle Jardin, Claire Senechal, Julien Guerin, Sophie Frank, Florence Coussy, Guillaume Bataillon, Diane De Croze
Publikováno v:
Cancers, Vol 12, Iss 3681, p 3681 (2020)
Cancers
Volume 12
Issue 12
Cancers
Volume 12
Issue 12
Introduction: Five to 10% of breast cancers (BCs) occur in a genetic predisposition context (mainly BRCA pathogenic variant). Nevertheless, little is known about immune tumor infiltration, response to neoadjuvant chemotherapy (NAC), pathologic comple
Autor:
Diane De Croze, Claire Senechal, Sonia Rozette, Isabelle Jardin, Fabien Reyal, Julien Guerin, Guillaume Bataillon, Dominique Stoppa-Lyonnet, Clemence Evrevin, Elise Dumas, Sophie Frank, Florence Coussy, Claire Saule, Marick Laé, Enora Laas, Lucie Laot, Jean-Yves Pierga, Anne-Sophie Hamy, Beatriz Grandal, Etienne Brain
IntroductionFive to 10% of breast cancers (BCs) occur in a genetic predisposition context (mainly BRCA pathogenic variant). Nevertheless, little is known about immune tumor infiltration, response to neoadjuvant chemotherapy (NAC), pathologic complete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::106ab697585b83fc31ed1a8eb34486b6
https://doi.org/10.1101/2020.09.27.20202515
https://doi.org/10.1101/2020.09.27.20202515
Autor:
Thomas Balezeau, Sonia Rozette, Fabien Reyal, Enora Laas, Diane De Croze, Jean-Yves Pierga, Lucie Laot, Elise Dumas, Julien Guerin, Vanille Simon, Judith Abecassis, Anne-Sophie Hamy, Marick Laé, Florence Coussy, Florence Lerebours, Beatriz Grandal, Marion Nicolas
Publikováno v:
Cancers
Volume 12
Issue 10
Cancers, Vol 12, Iss 2943, p 2943 (2020)
Volume 12
Issue 10
Cancers, Vol 12, Iss 2943, p 2943 (2020)
Tobacco use is associated with an increase in breast cancer (BC) mortality. Pathologic complete response (pCR) rate to neoadjuvant chemotherapy (NAC) is influenced by tumor-infiltrating lymphocyte (TIL) levels and is associated with a better long-ter
Autor:
Marie Osdoit, Jean-Guillaume Feron, Marick Laé, Jean-Yves Pierga, Florence Lerebours, Clemence Evrevin, Lauren Darrigues, Anne-Sophie Hamy, Fabien Reyal, Lucie Laot, Lucian Topciu, Enora Laas, Diane De Croze, Matthieu Faron, Sonia Rozette, Giang-Thanh Lam
Publikováno v:
PLoS ONE
PLoS ONE, Public Library of Science, 2020, 15 (6), pp.e0234191. ⟨10.1371/journal.pone.0234191⟩
PLoS ONE, 2020, 15 (6), pp.e0234191. ⟨10.1371/journal.pone.0234191⟩
PLoS ONE, Vol 15, Iss 6, p e0234191 (2020)
PLoS ONE, Public Library of Science, 2020, 15 (6), pp.e0234191. ⟨10.1371/journal.pone.0234191⟩
PLoS ONE, 2020, 15 (6), pp.e0234191. ⟨10.1371/journal.pone.0234191⟩
PLoS ONE, Vol 15, Iss 6, p e0234191 (2020)
IntroductionThe Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. The objective of this work is to independently evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e99a59ac4d86c59d814679dc4fd656ca
https://www.hal.inserm.fr/inserm-02905473/document
https://www.hal.inserm.fr/inserm-02905473/document
Autor:
Marion Nicolas, Julien Guerin, Fabien Reyal, Sonia Rozette, Lucie Laot, Diane De Croze, Enora Laas, Vanille Simon, Thomas Balezeau, Judith Abecassis, Anne-Sophie Hamy, Marick Laé, Florence Coussy, Beatriz Grandal, Jean-Yves Pierga
INTRODUCTIONTobacco use is associated with an increase in breast cancer (BC) mortality. Pathologic complete response rate to neoadjuvant chemotherapy (NAC) is influenced by tumor-infiltrating lymphocytes (TILs) levels and is associated with a better
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a24788911df4662bdc1a3bc1467cc343
https://doi.org/10.1101/2020.06.05.20123273
https://doi.org/10.1101/2020.06.05.20123273
Autor:
Marick Laé, Lucie Laot, Eric Daoud, Isabelle Jardin, Claire Senechal, Florence Coussy, Clara Sebbag, Sonia Rozette, Nadir Sella, Fabien Reyal, Sophie Franck, Beatriz Grandal, Elise Dumas, Clemence Evrevin, Diane De Croze, Anne-Sophie Hamy, Claire Saule, Dominique Stoppa-Lyonnet, Enora Laas
Publikováno v:
Cancer Research. 81:PS13-10
Context: The majority of BRCA mutation carriers diagnosed with breast cancer (BC) are treated with chemotherapy. The effectiveness of standard neoadjuvant chemotherapy (NAC) in BRCA associated BC compared to noncarriers has been poorly explored. Obje